ALKの活性化突然変異は,神経芽細胞腫の治療標的となる
Rani E George1, Takaomi Sanda, Megan Hanna
1Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nature
|October 17, 2008
まとめ
ALK遺伝子の新しい突然変異は,子供のがんである神経芽細胞腫で発見されました. これらのALK変異は,標的となるALK阻害剤に対して腫瘍を敏感にし,新しい治療戦略を提供する.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- 神経芽細胞腫は,外周交感性神経系から発生する致命的な小児がんです.
- 高リスクの神経芽細胞腫は,集中化学療法にもかかわらず,しばしば再発し,致命的です.
研究 の 目的:
- ニューロブラストーマにおける新しい遺伝子変異を特定する.
- 神経芽細胞腫の発達と進行におけるALK遺伝子の役割を調査する.
- 神経芽細胞腫の標的治療の選択肢を探求する.
主な方法:
- 原発性ニューロブラストーマ腫瘍におけるALK遺伝子の配列決定.
- 細胞系 (Ba/F3,ニューロブラストーマ細胞系) を用いた機能的研究.
- ALK阻害剤と遺伝子ノックダウンに対する感受性の評価.
主要な成果:
- ALK遺伝子のこれまで未知の変異は,原発性ニューロブラストーマの8%で検出されました.
- 特定のALK変異 (F1174L,R1275Q) は,Ba/F3細胞におけるサイトカイン依存の成長をもたらした.
- ALK変異を有するニューロブラストーマ細胞系は,ALK阻害剤とアポトーシス誘導に対する感受性を示した.
結論:
- 活性化ALK変異は神経芽細胞腫に存在し,腫瘍の成長を誘導する.
- ALKの標的抑制は,神経芽細胞腫に対する有望な治療戦略を提供します.
- この発見は,この攻撃的な小児がんに対する新しい治療法を開発するための分子基盤を提供します.
さらに関連する動画
関連する概念動画
Enzyme-linked Receptors
64.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K


